Revealed on April 17, the initial study on the new therapy will be presented at the 70th Annual Meeting of the American Academy of Neurology in Los Angeles.
Erenumab is a human monoclonal antibody which blocks the calcitonin gene-related peptide receptor (CGRPR) – a human protein that transmits pain signals during an attack as well as plays an important role in the development of migraines. Developed by Amgen Inc., this new drug may prevent hard-to-treat chronic migraine.
The study followed 246 people who suffered from the tough-to-treat migraines four to 14 times a month. The researchers gave either 140 milligrams of erenumab (injections) or a placebo to all the participants once a month for around three months. They found that participants who were given erenumab experienced a reduction in the number of days they had headaches.
“Our study found that erenumab reduced the average number of monthly migraine headaches by more than 50% for nearly a third of study participants. That reduction in migraine headache frequency can greatly improve a person’s quality of life,” said study author Dr. Uwe Reuter, of The Charité – University Medicine Berlin in Germany.
Dr. Reuter also said that further research is required to know how long the treatment will work. For now, the drug’s approval-related decision will be announced under review by the Food and Drug Administration (FDA), on May 17.